Abstract
Purpose
To Evaluate the safety and technical success of transgluteal CT-guided fiducial marker implantation into the prostate as an alternative method to transperineal and transrectal approaches.
Material and Methods
We retrospectively identified all patients who had undergone CT-guided transgluteal fiducial marker insertion between 2020 and 2022. Four patients with confirmed prostate cancer were identified. One radiologist performed all procedures via a bilateral transgluteal approach under the guidance of real-time CT-fluoroscopy. Twenty cm long pre-waxed 18G guiding needles, preloaded with smooth gold fiducial markers, were used to implant markers. Technical success was defined as the successful placement of the fiducial markers into the planned positions.
Results
The mean age of patients was 70 years. The mean procedure time was 19.25 (SD: 6.75) min, and the mean total dose length product (DLP) was 801.75 (SD: 291.17) mGycm, which is compatible with the 12 mSv estimated effective dose. All procedures were technically successful (100%). All patients tolerated the procedure and did not require any analgesia for pain, and there were no requests to stop or pause the procedure. Only one patient reported hematuria one day after the procedure, which required no treatment.
Conclusion
Transgluteal CT-guided fiducial marker implantation into the prostate is an alternative method to transperineal and transrectal approaches. In this technique, the risk of septic complications is minor, and general anesthesia is not required. Thus, transgluteal CT-guided marker insertion is a feasible and well-tolerated method for image-guided radiation therapy (IGRT) in patients with prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Iocolano M, et al. Prostate fiducial marker placement in patients on anticoagulation: feasibility prior to prostate SBRT. Front Oncol. 2020;10:203.
Kably I, et al. Single-center experience in prostate fiducial marker placement: technique and midterm follow-up. J Vasc Interv Radiol. 2014;25(7):1125-1132.e1.
Loh J, et al. Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? Radiat Oncol. 2015;10(1):38.
Hogan D, et al. Local versus general anesthesia transperineal prostate biopsy: tolerability, cancer detection, and complications. BJUI Compass. 2021;2(6):428–35.
Gill S, et al. Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy. Br J Radiol. 2012;85(1015):1011–7.
McGee LA, et al. Prostate fiducial marker placement using a transperineal approach results in low rates of post procedure complications. Int J Radiat Oncol Biol Phys. 2015;93(3):E218.
Langenhuijsen JF, et al. Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: complication rate and risk factors. Int J Radiat Oncol Biol Phys. 2007;69(3):671–6.
Moman MR, et al. Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol. 2010;96(1):38–42.
Wagenlehner FME, et al. infective complications after prostate biopsy: outcome of the global prevalence study of infections in urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013;63(3):521–7.
Grummet JP, et al. Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int. 2014;114(3):384–8.
Patel N, Coakley FV, Foster BR. Performance of transgluteal CT-guided biopsy of prostate lesions in men without rectal access: a retrospective study. Clinic Imaging. 2021;79:225–9.
Olson MC, et al. CT-guided transgluteal biopsy for systematic sampling of the prostate in patients without rectal access: a 13 year single-center experience. Eur Radiol. 2017;27(8):3326–32.
Kirsch AJ, Coakley FV, Foster BR. A modified approach for transgluteal prostate biopsy in patients without rectal access. AJR Am J Roentgenol. 2016;207(2):W20.
Goenka AH, et al. CT-guided transgluteal biopsy for systematic random sampling of the prostate in patients without rectal access. AJR Am J Roentgenol. 2015;205(3):578–83.
Caglic I, et al. Lesion targeted CT-guided transgluteal prostate biopsy in combination with prebiopsy MRI in patients without rectal access. Urol Case Rep. 2017;10:6–8.
Bodelle B, Naguib NN, Schulz B, Eichler K, Müller C, Hansmann M-L, Hammerstingl R, Hübner F, Vogl TJ, Zangos S. 1.5-T magnetic resonance–guided transgluteal biopsies of the prostate in patients with clinically suspected prostate cancer: technique and feasibility. Invest Radiol. 2013;48(6):458–63.
Acknowledgements
None
Funding
This study was not supported by any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Consent for Publication
Consent for publication was obtained for every individual person’s data included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Khanmohammadi, S., Golzarian, J. & Akhlaghpoor, S. CT-guided Transgluteal Prostate Fiducial Marker Insertion for Localized Radiation Therapy. Cardiovasc Intervent Radiol 46, 1409–1413 (2023). https://doi.org/10.1007/s00270-023-03539-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-023-03539-2